A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared with Placebo in Subjects with Obesity and in Subjects with Type 2 Diabetes Mellitus (T2DM)
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs PG 102 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
- 11 Dec 2024 Status changed from not yet recruiting to recruiting.
- 09 Dec 2024 New trial record